Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Conavi Medical Corp. has filed a preliminary prospectus for a public offering of common shares and pre-funded warrants in connection with a limited market release in the United States. The offering, expected to close on or about May 28, 2026, is subject to regulatory approvals and will be coordinated by Bloom Burton on behalf of a syndicate of agents. The proceeds will be used for working capital and corporate purposes. The company’s Novasight Hybrid™ System is designed to assist minimally invasive cardiovascular procedures.
TORONTO, May 11, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today that it has filed a preliminary short form prospectus (the “Preliminary Prospectus”) with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with an offering (the “Offering”) of common shares of the Company (“Common Shares”) and/or pre-funded common share purchase warrants of the Company (“Pre-Funded Warrants” and, together with the Common Shares, the “Securities”) in lieu of Common Shares.